In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Benefits and safety of exercise training in patients with severe three coronary vessels disease.

Session Poster Session 1

Speaker Hermes Ilarraza-Lomeli

Event : ESC Congress 2019

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Exercise Programmes
  • Session type : Poster Session

Authors : J Rojano (Mexico City,MX), H Ilarraza Lomeli (Mexico City,MX), M Garcia Saldivia (Mexico City,MX), M Rius Suarez (Mexico City,MX), A Lopez Garcia (Mexico City,MX), JC Perez Gamez (Mexico City,MX), E Franco Ojeda (Mexico City,MX), R Chavez Dominguez (Mexico City,MX)

J Rojano1 , H Ilarraza Lomeli1 , M Garcia Saldivia2 , M Rius Suarez1 , A Lopez Garcia1 , JC Perez Gamez2 , E Franco Ojeda1 , R Chavez Dominguez1 , 1National Institute of Cardiology Ignacio Chavez - Mexico City - Mexico , 2Hospital of Cardiology at the Siglo XX National Medical Center - Mexico City - Mexico ,


Background. Coronary heart disease is the leading cause of death in the world. Nowadays, there are still patients with untreatable coronary obstructions and exercise therapy could be an option to improve their quality of life and probably diminish mortality. Cardiac rehabilitation programs are recommended worldwide due its effectiveness and safety. However very high risk patients are often not included.
Purpose: To evaluate the benefit and safety of exercise therapy as a part of a cardiac rehabilitation program in patients with untreatable severe coronary heart disease.
Methods:  A cohort of patients with coronary heart disease included in a cardiac rehabilitation program were studied. Those with severe coronary heart disease (Syntax score =33, group A) were identified. Patients were stratified using clinical records and cardiopulmonary exercise testing.  They trained for 30 minutes, five times a week of aerobic exercise (cycle ergometer) and this therapy was complemented with general strength, coordination, balance and flexibility maneuvers. After twenty exercise sessions, a second cardiopulmonary exercise test was performed. Symptom limited cardiopulmonary exercise testing was undertaken using a ramp Balke protocol and cardiopulmonary variables were recorded. These patients were compared with their counterparts without severe coronary heart disease (Control group, group B). Studied variables were presented as frequencies (%), mean (SD), median (range) as appropriate. Comparisons between groups were made using chi square or paired T test as needed. All p values <0.05 were considered stochastically significant.
Results: From a total of 546 patients, seventy-one had severe coronary heart disease (Syntax score =33). There were no significant differences between groups on change of METs value and number of sessions assisted. No major adverse cardiovascular outcome was observed. The percentage of exercise induced arrhythmias was 75% in very high risk group vs 76% in control group, (p >0.05). Results are shown in table 1.
Conclusion: Exercise training could be performed in an effective and safe manner in patients with very high risk untreated coronary heart disease.


Group A


Group B


p value
Assisted training sessions 15±7



Increment in MET(ml/kg/min)







Angor/ST depression(n,%)

11(15) 15(3) <0.01
Differences in workload(Watts) 20±13 22±13 ns

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are